Trials / Completed
CompletedNCT04355624
Kidney Involvement in COVID-19 Disease (COVKID)
Characterization of Kidney Involvement in COVID-19 Disease: a French Multi-center Prospective Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 45 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Nice · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Novel coronavirus disease (COVID-19) is a newly discovered contagious disease caused by SARS-CoV-2 virus, primarily manifesting as an acute respiratory illness with pneumonia, but can affect multiple organs such as kidney, heart, digestive tract, blood and nervous system. In previous reports of SARS and MERS-CoV infections, acute kidney injury was described in 5 to 15% of patients and was associated with a high mortality rate (60-90%). Recent reports showed renal abnormalities in COVID-9 infected patients. A recent Chinese study also reported that acute kidney injury was an independent risk factor for mortality. However, the exact mechanism of kidney involvement remains unclear: sepsis-related cytokine storm or direct cellular injury from the virus. Also, kidney involvement has not yet been well characterized: heavy albuminuria, hematuria or interstitial nephropathy alone. A recent study identified viral RNA in kidney tissue and another study succeeded isolating SARS-CoV-2 from the urine sample of an infected patient. These data suggest that the kidney might be a target of this novel coronarivus. The sponsor suggests characterizing kidney involvement in SARS-CoV-2 infection. Study objectives are: * To give an accurate characterization of kidney involvement in COVID-19 * To investigate the physiopathologic mechanism of kidney involvement in SARS-CoV-2 infection * To identify risk factors for kidney involvement in in SARS-CoV-2 infection * To evaluate the impact of kidney involvement in in SARS-CoV-2 infection * To assess the long-term health effect of kidney injury on survivors of in SARS-CoV-2 infection
Conditions
Timeline
- Start date
- 2020-04-15
- Primary completion
- 2020-04-19
- Completion
- 2020-04-19
- First posted
- 2020-04-21
- Last updated
- 2025-04-03
Locations
4 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04355624. Inclusion in this directory is not an endorsement.